Jaguar Health, Inc. 8-K

What Happened Jaguar Health, Inc. (JAGX) filed an 8‑K reporting that on March 5, 2026 it received a written notice from Nasdaq’s Listing Qualifications staff that the company is not in compliance with Nasdaq Listing Rule 5550(a)(2) because the bid price for its common stock closed below the $1.00 minimum for the previous 30 consecutive business days. Nasdaq further stated the company is ineligible for the usual compliance period under Nasdaq Listing Rule 5810(c)(3)(A) because the company effected a reverse stock split within the prior one‑ to two‑year period with a cumulative ratio of 250 to 1 (per Rule 5810(c)(3)(A)(iv)). Nasdaq indicated the securities would be scheduled for delisting unless Jaguar Health timely requests an appeal by March 12, 2026. The company intends to request an appeal, which will automatically stay any suspension or delisting pending the hearing process. The filing also includes standard forward‑looking statement disclosures.

Key Details

• Notice received from Nasdaq on March 5, 2026 for non‑compliance with Rule 5550(a)(2) (minimum $1.00 bid price).
• Stock closed below $1.00 for the prior 30 consecutive business days per Nasdaq’s determination.
• Ineligible for a compliance period under Rule 5810(c)(3)(A) due to reverse split(s) within the prior 1–2 years with cumulative ratio of 250:1.
• Deadline to request an appeal is March 12, 2026; Jaguar Health intends to request an appeal, which stays delisting pending the hearings panel decision.

Why It Matters A Nasdaq delisting would remove Jaguar Health’s listing on Nasdaq, which can materially affect share liquidity, visibility and the company’s ability to raise capital. While the company has filed to appeal—pausing any immediate delisting action—there is no assurance the Nasdaq Hearings Panel will grant continued listing or that Jaguar Health will regain compliance. Investors should monitor further SEC filings and company updates for the outcome of the appeal and any plans to restore compliance.